<DOC>
	<DOCNO>NCT02920385</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate influence oral semaglutide pharmacokinetics ( exposure trial drug body ) levothyroxine influence co-administered tablet pharmacokinetics semaglutide administer orally healthy subject .</brief_summary>
	<brief_title>A Trial Investigating Influence Oral Semaglutide Pharmacokinetics Levothyroxine Influence Co-administered Tablets Pharmacokinetics Semaglutide Administered Orally Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Male female age 1850 year ( inclusive ) time sign informed consent Body mass index ( BMI ) 20.0 29.9 kg/m^2 ( inclusive ) Considered generally healthy base medical history , physical examination , result vital sign , electrocardiogram clinical laboratory test perform screen visit , judge investigator Smoker ( define subject smoking least 1 cigarette equivalent per day ) Unable unwilling refrain smoking use nicotine substitute product within 48 hour prior inpatient period Any blood draw excess 25 mL past 30 day , donation blood plasma excess 400 mL within 90 day precede screen History ( declare subject ) major surgical procedure involve stomach potentially affect absorption trial product ( e.g . subtotal total gastrectomy , sleeve gastrectomy , gastric bypass surgery ) History ( declare subject ) presence clinical nonclinical thyroid disease , include thyroid palpation abnormality , level T3 T4 ( total free ) TSH outside reference limit , presence thyroid antibody ( Thyroid Stimulating Hormone Receptor Antibody , Thyroperoxidase Antibody Thyroid Antithyroglobulin Antibodies )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>